Kura Oncology, Inc. (KURA) vs LB Pharmaceuticals Inc Common Stock (LBRX)
A side-by-side comparison of Kura Oncology, Inc. and LB Pharmaceuticals Inc Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
KURA
Kura Oncology, Inc.
$10.69HealthcareDelayed quote: Oct 6, 2026, 12:50 PM EDT
LBRX
LB Pharmaceuticals Inc Common Stock
$34.20HealthcareDelayed quote: Oct 6, 2026, 12:50 PM EDT
Total return — KURA vs LBRX
growth of $100 · dividends reinvested · last 1yKURA +20.4% (+20.4%/yr)LBRX +100.1% (+100.1%/yr)LBRX compounded faster over this window
KURA LBRX
KURA vs LBRX: by the numbers
- •LBRX is the larger company ($981M vs $949M market cap).
- •Both run net losses; LBRX's is the smaller (0.00% vs -384.30% net margin).
Metrics side by side
Valuation
| Metric | KURA | LBRX |
|---|---|---|
| P/S ratio | 12.29 | N/A |
| P/B ratio | 19.59 | 2.95 |
Profitability
| Metric | KURA | LBRX |
|---|---|---|
| Gross margin | 94.73% | 0.00% |
| Operating margin | -449.94% | 0.00% |
| Net margin | -384.30% | 0.00% |
| ROE | -612.78% | -25.78% |
| ROIC | -67.13% | -28.14% |
Growth (annualized)
| Metric | KURA | LBRX |
|---|---|---|
| Total return CAGR (5Y) | -10.73% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.